- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.06. | Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks | ||
| 02.06. | Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial | ||
| 02.06. | Praxis pauses one of its seizure programs after phase 2 fail | ||
| 01.06. | At ASCO 2026, a 'paradigm shift' for a rare gut cancer looms | ||
| 01.06. | Agios signs $165M deal for blood disorder drug from Korea's Oscotec that flunked phase 2 study | ||
| 01.06. | Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo | ||
| 01.06. | Servier inks $2.6B buyout of Edgewise's muscular dystrophy unit to beef up neurology pipeline | ||
| 01.06. | Lilly locks in 5-program R&D pact with China's Haisco worth up to $3B, but targets unclear | ||
| 01.06. | Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome | ||
| 30.05. | In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach | ||
| 29.05. | Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform | ||
| 29.05. | AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval | ||
| 29.05. | Agios' next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed | ||
| 29.05. | Boston, China and the future of biotech | ||
| 29.05. | Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field | ||
| 29.05. | Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation | ||
| 28.05. | FDA extends Beren's rare disease review after info request, further stretching saga | ||
| 28.05. | Hoth Therapeutics' pivot to AI in space sees stock rocket after rebrand | ||
| 27.05. | D&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug | ||
| 27.05. | Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3 | ||
| 27.05. | Kardigan itching for IPO to fund late-stage cardiovascular pipeline | ||
| 26.05. | As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing? | ||
| 26.05. | Makary's FDA reforms 'continue to move forward' despite leadership turmoil | ||
| 26.05. | Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors' potential | ||
| 26.05. | Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.